Refine
Has Fulltext
- yes (40)
Is part of the Bibliography
- yes (40)
Year of publication
Document Type
Keywords
- Toxikologie (17)
- DNA damage (9)
- micronuclei (4)
- Micronuclei (3)
- oxidative stress (3)
- 5-Azacytidine (2)
- DNA repair (2)
- Diethylstilbestrol (2)
- Electropermeabilization (2)
- Elektrofusion (2)
- Elektroporation (2)
- Zelle (2)
- actinomycetes (2)
- apoptosis (2)
- cancer risk (2)
- comet assay (2)
- cytokinins (2)
- insulin (2)
- lymphocytes (2)
- (Mouse L-cell) (1)
- 1 (1)
- 2-Dioxetane (1)
- 6-benzylaminopurine (1)
- Alzheimers disease (1)
- Benzefuran dioxetane (1)
- Benzefuran epoxide (1)
- Berenil (1)
- Bromodeoxyuridine labeling (1)
- Calcium (1)
- Cell death and comet assay (1)
- Cell transformation (1)
- Chromosome distribution (1)
- DES (1)
- DNA adduct . Repair endonuclease (1)
- DNA damage response (1)
- DNA transfection (1)
- DNS-Schädigung (1)
- Drug resistance (1)
- Electric Field (1)
- Electrical breakdown (1)
- Ethionine (1)
- Eukaryotic cell (1)
- FPG protein (1)
- Flow cytometry (1)
- Gene Transfer (1)
- Gene transfer (1)
- Hoechst 33258 dye (1)
- Hybridoma (1)
- Kinetochore (1)
- Kinetochores (1)
- L5178Y cells (1)
- Medizin (1)
- Micronucleus formation (1)
- Mitosis (1)
- Mutagenicity (1)
- Neomycin Resistance (1)
- Salmonella/microsome assay (1)
- Stable Transformation (1)
- Streptomyces (1)
- TK6 cells (1)
- Toxin (1)
- Transfection (1)
- Unscheduled DNA synthesis (1)
- Volume distribution (1)
- Wachstumskonus (1)
- Zellskelett (1)
- ageing (1)
- antibacterial/antiviral drug (1)
- antioxidants (1)
- assay (1)
- association (1)
- bariatric surgery (1)
- base excision repair (incision activity) (1)
- biofilms (1)
- biology (1)
- biomarkers (1)
- blood samples (1)
- calcium (1)
- cell fate (1)
- cell staining (1)
- chronic kidney disease (1)
- co-culture (1)
- cognitive impairment (1)
- contact lens (1)
- continuous (1)
- cyclic dipeptide (1)
- cytochrome P450s (1)
- cytome biomarkers (1)
- cytoskeleton (1)
- cytotoxic (1)
- diabetes (1)
- diagnosis (1)
- dialysis (1)
- etoposide (1)
- fatty liver (1)
- fluorescence recovery after photobleaching (1)
- genomic damage (1)
- genotoxicity (1)
- growth cone (1)
- haematopoietic stem cells (1)
- human biomonitoring (1)
- insulin signaling (1)
- life (1)
- live imaging (1)
- liver (1)
- lovastatin (1)
- mTOR-inhibitor RAD-001 (1)
- maintenance of genomic integrity (1)
- mammalian genomics (1)
- marine sponges (1)
- medicine (1)
- membrane transporters (1)
- micronucleus test (1)
- mitotic disturbance (1)
- mouse lymphoma L5178Y (1)
- mouse models DNA damage (1)
- mutagenicity (1)
- obesity (1)
- peripheral-blood lymphocytes (1)
- poly(ADP-ribosyl)ation (1)
- pyrrolizidine alkaloids (1)
- rat pheochromocytoma cells (1)
- resveratrol (1)
- sex (1)
- sponges (1)
- staphilococci (1)
- streptomyces (1)
- thyroid hormone (1)
- uremic toxins (1)
Institute
- Institut für Pharmakologie und Toxikologie (40) (remove)
EU-Project number / Contract (GA) number
- 311932 (2)
The antidepressant fluoxetine has been under discussion because of its potential influence on cancer risk. It was found to inhibit the development of carcinogen-induced preneoplastic lesions in colon tissue, but the mechanisms of action are not well understood. Therefore, we investigated anti-proliferative effects, and used HT29 colon tumor cells in vitro, as well as C57BL/6 mice exposed to intra-rectal treatment with the carcinogen N-methyl-N’-nitro-N-nitrosoguanidine (MNNG) as models. Fluoxetine increased the percentage of HT29 cells in the G0/G1 phase of cell-cycle, and the expression of p27 protein. This was not related to an induction of apoptosis, reactive oxygen species or DNA damage. In vivo, fluoxetine reduced the development of MNNG-induced dysplasia and vascularization-related dysplasia in colon tissue, which was analyzed by histopathological techniques. An anti-proliferative potential of fluoxetine was observed in epithelial and stromal areas. It was accompanied by a reduction of VEGF expression and of the number of cells with angiogenic potential, such as CD133, CD34, and CD31-positive cell clusters. Taken together, our findings suggest that fluoxetine treatment targets steps of early colon carcinogenesis. This confirms its protective potential, explaining at least partially the lower colon cancer risk under antidepressant therapy.